Novo Nordisk (NOVO-B) Stock Price, Fundamentals & Analysis

What NOVO-B does

Novo Nordisk (NOVO-B) is a Danish pharmaceutical company headquartered in Bagsvaerd, Denmark, with 66,700 employees. It researches, manufactures, and distributes products across three main areas: obesity and diabetes care, rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Its portfolio includes smart insulin pens such as the NovoPen 6 and NovoPen Echo Plus, the Dose Check insulin dose guidance application, growth hormone pens and injection needles, and Wegovy pill, an oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight management. The company also has a collaboration with Anthropic to accelerate the development of new medicines and advance AI-driven software development. Novo Nordisk operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. In Denmark, it is part of the OMXC25 index and sits alongside peers such as Coloplast (COLO-B), GN Store Nord (GN), Genmab (GMAB), Ambu (AMBU-B), and Demant (DEMANT).

Key numbers explained

• 253 DKK is the current share price, the amount you would pay for one share on the Nasdaq Copenhagen market.
• The trailing P/E ratio of 9.6 shows the price investors pay per unit of the last 12 months' earnings; a lower figure can suggest the stock is priced more conservatively relative to recent earnings.
• The forward P/E ratio of 11.6 uses expected future earnings, giving a sense of how the market values the company's growth outlook.
• 26.26 DKK is the earnings per share over the trailing 12 months, representing the portion of the company's profit allocated to each outstanding share.
• The dividend yield of 4.62% indicates the annual dividend payment as a percentage of the current share price, a common way to compare income returns across stocks.
• The ex-dividend date of Aug 14, 2026 is the cutoff: you must own the stock before this date to receive the next dividend payment.
• A beta of 0.34 suggests the stock has historically been less volatile than the overall market, often interpreted as a defensive characteristic.
• The 52-week range of 224.25 – 409.95 DKK shows the lowest and highest prices over the past year, while the -28% price change over that period reflects the decline from the year-ago level.

What to watch

Investors tracking Novo Nordisk (NOVO-B) commonly monitor its upcoming earnings release on Nov 4, 2026, which can influence short-term price movements. The company's exposure to the GLP-1 receptor agonist market, including Wegovy pill, places it at the center of obesity and diabetes care trends. Regulatory decisions, clinical trial results, and competitive dynamics in the drug manufacturers sector are general factors that can affect stocks like NOVO-B. Its position in the Healthcare sector and its dividend policy, with 45% of earnings paid out as dividends, are also relevant for long-term investors. For broader context, you can explore other Danish stocks on the Nasdaq Copenhagen stocks page or the full stocks directory.